Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VH5356136 Formulation 1, VH5356136 Formulation 2
VH5356136 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
| Arm | Type | Description |
|---|---|---|
| VH5356136 Formulation 1 | EXPERIMENTAL | Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1. |
| Placebo for VH5356136 Formulation 1 | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1. |
| VH5356136 Formulation 2 | EXPERIMENTAL | Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1. |
| Placebo for VH5356136 Formulation 2 | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1. |
| Name | Type | Description |
|---|---|---|
| VH5356136 Formulation 1 | DRUG | Participants will receive VH5356136 Formulation 1 on Day 1. |
| VH5356136 Formulation 2 | DRUG | Participants will receive VH5356136 Formulation 2 on Day 1. |
| Placebo for VH5356136 Formulation 1 | DRUG | Participants will receive placebo for VH5356136 Formulation 1 on Day 1. |
| Placebo for VH5356136 Formulation 2 | DRUG | Participants will receive placebo for VH5356136 Formulation 2 on Day 1. |
Inclusion Criteria: * Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF). * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * ...
Top 18 of 27 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 5 | PHASE3 | VLA15, ATM-AVI, PG4, Prevenar 20 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |